AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

A Natural Compound from Garcinia yunnanensis Hu for Treatment of Esophageal Cancer

Summary
This invention relates to a chemical entity isolated from natural sources for its therapeutic uses. More particularly, it relates to compound that is naturally occurring in the plant of Garcinia yunnanensis Hu and its biological activity of antitumor effects.
Technology Benefits
Guttiferone K is the most potent PPAP compound, which had potent cytotoxic effects on human colorectal cancer cell lines without affecting the normal human colon fibroblasts
Technology Application
Guttiferone K can be developed as anticancer drug against esophageal cancer.
Detailed Technology Description
From our previous screen on human colon cancer HT-29 cell line, Guttiferone K is the most potent PPAP compound. In this invention, we found that Guttiferone K can significantly inhibit esophageal cancer cell (ESCC) ECA109 migration and invasion.
Supplementary Information
Inventor: BLOOM, Stephen, Robert | GHATEI, Mohammad, Ali
Priority Number: WO2006134340A9
IPC Current: C07K0014605 | A61K003826 | A61P000304
Assignee Applicant: Imperial Innovations Limited
Title: OXYNTOMODULIN ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR | NOUVEAUX COMPOSES ET LEURS EFFETS SUR LE COMPORTEMENT ALIMENTAIRE
Usefulness: OXYNTOMODULIN ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR | NOUVEAUX COMPOSES ET LEURS EFFETS SUR LE COMPORTEMENT ALIMENTAIRE
Summary: The compounds are useful as a medicament or for the manufacture of a medicament for the treatment of obesity or diabetes, and for the reduction of appetite in a subject, for the reduction of food intake in a subject, for the reduction of calorie intake in a subject, reducing the body weight of a subject, reducing body weight gain in a subject, or increasing energy expenditure in a subject (claimed).
Novelty: New compound, which is a peptide analogue of oxyntomodulin (oxm), useful for treating obesity or diabetes, and for reducing appetite, food intake, calorie intake, or body weight of a subject
Industry
Chemical/Material
Sub Category
Chemical/Material Application
Application Date
2013.01.10
Application No.
US 61/750,969
Others
Filed
ID No.
A61/BZ/Gutt/US0P
Country/Region
Hong Kong

For more information, please click Here
Mobile Device